We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GEV:NYSEGE Vernova Inc. Analysis

Data as of 2026-03-09 - not real-time

$830.10

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

GE Vernova (GEV) is trading at $830.1, just below its 20‑day SMA of $833.6 but comfortably above the 50‑day ($743.7) and 200‑day ($623.8) averages, indicating a short‑term bullish bias within a longer‑term uptrend. The RSI of 55.4 suggests neutral momentum, while the MACD histogram is negative and the signal line is bearish, hinting at possible near‑term weakness. Volume is on an increasing trend and the beta of 1.55 combined with a 30‑day volatility of 44% points to a highly responsive price action. Fundamentally, the stock appears overvalued: a trailing P/E of 46.9 far exceeds the industry average of 29.5, and the DCF‑derived fair value of $345.6 is less than half the current price, yielding a modest upside/downside estimate of only 1.5%. However, the company boasts a strong balance sheet with $8.9 B cash, low debt ($1.2 B) and a debt‑to‑equity ratio of 9.7, an impressive ROE of 42.6%, and a sustainable dividend payout of 0.19% with a 7% payout ratio. These dynamics suggest that while the stock is currently pricey, its solid cash generation and low leverage provide a cushion against downside risks.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price holding above key support at $771 and near 20‑day SMA
  • Increasing volume supporting bullish momentum
  • Neutral RSI with room for upside before overbought conditions

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Significant valuation gap between market price and DCF fair value
  • Strong cash flow and low leverage providing downside protection
  • Potential corrective pressure from high P/E relative to peers

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • High ROE (42.6%) indicating efficient capital use
  • Exposure to renewable energy and grid‑modernization trends
  • Low dividend payout allowing reinvestment into growth initiatives

Key Metrics & Analysis

Financial Health

Revenue Growth3.80%
Profit Margin12.83%
P/E Ratio47.0
ROE42.64%
ROA2.34%
Debt/Equity9.73
P/B Ratio20.0
Op. Cash Flow$5.0B
Free Cash Flow$5.3B
Industry P/E29.5

Technical Analysis

TrendBullish
RSI55.4
Support$771.01
Resistance$894.93
MA 20$833.63
MA 50$743.69
MA 200$623.81
MACDBearish
VolumeIncreasing
Fear & Greed Index100

Valuation

Fair Value$345.59
Target Price$842.62
Upside/Downside1.51%
GradeOvervalued
TypeGrowth
Dividend Yield0.19%

Risk Assessment

Beta1.55
Volatility44.14%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.